- Home
- VOR vs VTYX Comparison
VOR vs VTYX Comparison
Compare VOR & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- VTYX
- Stock Information
- Founded
- VOR 2015
- VTYX 2018
- Country
- VOR United States
- VTYX United States
- Employees
- VOR N/A
- VTYX N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- VOR Health Care
- VTYX Health Care
- Exchange
- VOR Nasdaq
- VTYX Nasdaq
- Market Cap
- VOR 161.9M
- VTYX 154.9M
- IPO Year
- VOR 2021
- VTYX 2021
- Fundamental
- Price
- VOR $1.43
- VTYX $2.02
- Analyst Decision
- VOR Strong Buy
- VTYX Buy
- Analyst Count
- VOR 7
- VTYX 4
- Target Price
- VOR $11.36
- VTYX $11.33
- AVG Volume (30 Days)
- VOR 1.1M
- VTYX 1.9M
- Earning Date
- VOR 11-07-2024
- VTYX 02-25-2025
- Dividend Yield
- VOR N/A
- VTYX N/A
- EPS Growth
- VOR N/A
- VTYX N/A
- EPS
- VOR N/A
- VTYX N/A
- Revenue
- VOR N/A
- VTYX N/A
- Revenue This Year
- VOR N/A
- VTYX N/A
- Revenue Next Year
- VOR N/A
- VTYX N/A
- P/E Ratio
- VOR N/A
- VTYX N/A
- Revenue Growth
- VOR N/A
- VTYX N/A
- 52 Week Low
- VOR $0.63
- VTYX $1.67
- 52 Week High
- VOR $2.50
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- VOR 59.93
- VTYX 43.62
- Support Level
- VOR $1.27
- VTYX $1.83
- Resistance Level
- VOR $1.76
- VTYX $2.13
- Average True Range (ATR)
- VOR 0.18
- VTYX 0.17
- MACD
- VOR -0.01
- VTYX -0.02
- Stochastic Oscillator
- VOR 50.67
- VTYX 23.87
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.